BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Kite begins third study to back registration of lead CAR T-cell program
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Kite begins third study to back registration of lead CAR T-cell program
Dec. 3, 2015
By
Michael Fitzhugh
No Comments
Kite Pharma Inc. is kicking off its ZUMA-3 study, the third in what's soon to be a quartet of pivotal studies aimed at supporting regulatory approval of KTE-C19, its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and lead candidate.
BioWorld